Meeting
2022 ASCO Genitourinary Cancers Symposium
Survival outcomes in men with unfavorable intermediate-risk and high-risk prostate cancer treated with prostate-only versus whole pelvic radiation therapy.
Authors
Neal Andruska
Department of Radiation Oncology, Washington University School of Medicine, Saint Louis, MO
Neal Andruska , Benjamin Walker Fischer-Valuck , Elizabeth Juarez Diaz , Temitope Agabalogun , Randall Brenneman , Hiram Alberto Gay , Jeff M. Michalski , Brian C. Baumann
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Therapeutics
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 264)
DOI
10.1200/JCO.2022.40.6_suppl.264
Abstract #
264
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
Body fat composition as biomarker for clinical outcomes and treatment tolerance in high-risk prostate cancer.
First Author: Anurag Saraf
Poster
2019 Genitourinary Cancers Symposium
External beam radiation therapy and brachytherapy boost versus radical prostatectomy and adjuvant radiation therapy for high-risk prostate cancer.
First Author: Vinayak Muralidhar
Poster
2018 Genitourinary Cancers Symposium
Three-month post-treatment PSA as a biomarker of treatment response in intermediate or high-risk prostate cancer treated with androgen deprivation therapy and radiotherapy.
First Author: Bryant Alex
Poster
2024 ASCO Breakthrough
Changes in the treatment landscape of metastatic hormone-sensitive prostate cancer: A multicenter study.
First Author: Fumihiko Urabe